As such, increased expression of Smad7 and repression of Smad2 and Smad3 expression are characteristics of the early TGF-β signature as defined by Coulouarn and colleagues [15] whereas mutations in the cell-cycle inhibitor p16INK4 are present in most HCC [16]. The gene discussed is SMAD3; the disease is hepatocellular carcinoma.